Aldoxorubicin (aldoxo) is a prodrug of doxo that binds serum albumin through an integrated acid-sensitive linker, thereby increasing its half-life time and tumor specificity as the linker is mainly hydrolyzed in the acidic environment of the tumor. This evidence concerns the gene ALB and neoplasm.